A host of biotech startups in China have been making the trek to the US to partner on promising experimental therapies. And we have news of two new pacts this week:
→ Shanghai-based Antengene Corporation inked a collaborative partnership and definitive licensing agreement with Celgene Corporation for its TORC1/TORC2 inhibitor CC- 223 covering China and other Asian nations. Antengene will be fully responsible for the clinical development and commercialization of CC-223 for the defined territories.
→ Ionis Pharmaceuticals bagged a deal to collaborate with a small Chinese biotech on RNAi. Suzhou Ribo Life Science Co. will develop and commercialize RNA-targeted therapeutics in China after Ionis granted Ribo a license for the commercial rights to two Ionis Generation 2+ antisense drugs in metabolic disease and cancer, and an option to license a third pre-specified Generation 2+ antisense drug. In addition, Ribo will be responsible for conducting a multi-year research and drug discovery program to identify drugs that utilize Ionis’ ssRNAi technology. Ionis will receive an undisclosed up-front payment and equity in Ribo.
→ Belgium’s Galapagos NV has raised $338 million in a share offering.
→ Motif Bio $MTFB says it gathered positive topline results from REVIVE-1, a global Phase III clinical trial of its investigational drug candidate iclaprim in patients with acute bacterial skin and skin structure infections. Iclaprim achieved the primary endpoint of non-inferiority (10% margin) compared to vancomycin at the early time point, 48 to 72 hours after the start of administration of the study drug.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription